



Derik E. Haggard^{1,2}, R. Woodrow Setzer², Richard S. Judson², Katie Paul Friedman²

Derik E. Haggard | haggard.derik@epa.gov | 919-541-0745

Background:

- Endocrine disruption is a toxicity of both physiological and regulatory importance; as steroid hormones regulate reproduction, development, and other biological processes, it is a priority to identify chemicals that may interact with production of these hormones.
- A high-throughput H295R assay (HT-H295R) was developed as part of the U.S. EPA's ToxCast program that includes measurement of 11 hormones across the steroid hormone biosynthesis pathway in H295R cells, including progestagens, corticosteroids, androgens, and estrogens.
- HT-H295R has been used to screen a total of 2012 chemicals in single-concentration and 656 chemicals in multi-concentration.

Mahalanobis Distance Metric:

- We previously developed a statistical metric using the mean Mahalanobis distance (mMd) to quantify the effect of a chemical on the overall steroidogenesis pathway in HT-H295R.
- Mahalanobis distance incorporates the effect size for each steroid hormone measure after adjusting for covariance between the steroid hormone measures (Equation 1).
- The maximum mMd (maxmMd) value for each chemical was selected to indicate the magnitude of steroidogenesis pathway perturbation.

$$\text{Eq. 1} \quad mMD = \sqrt{(\mathbf{y}_c - \mathbf{y}_1)' \Sigma^{-1} (\mathbf{y}_c - \mathbf{y}_1) / N_h}$$

Where y_j is the vector of log-transformed hormone concentrations for the j^{th} concentration, N_h is the number of hormones with measurements for this chemical, and Σ is the estimate of the covariance matrix

Primary Questions:

- Is the covariance structure stable when you only use low or high responding chemicals for the mMd calculation (*i.e.* if the dataset changed), and how does this influence resulting mMd values?
- How well did we approximate the type I error rate, and what is the sensitivity of the mMd approach to detect significant perturbations with different effect sizes and steroid hormone responses?
- Do putative aromatase inhibitors have a unique steroid hormone pattern in HT-H295R?
- Can high-throughput screening markers of cytotoxicity and mitotoxicity be used to contextualize the mMd as a prioritization metric?

```

graph LR
    Input[TCPL HT-H29SR Level 0 Data] --> Partition[Partition Data from Original maxmMds]
    Partition --> DMSO1[DMSO]
    Partition --> Lower1[Lower]
    Partition --> Middle1[Middle]
    Partition --> Upper1[Upper]
    DMSO1 --> DMSO2[DMSO]
    Lower1 --> Lower2[Lower]
    Middle1 --> Middle2[Middle]
    Upper1 --> Upper2[Upper]
    DMSO2 --> Est1[Block Covariance Estimation]
    Lower2 --> Est1
    Middle2 --> Est1
    Upper2 --> Est1
    Est1 --> MVN[MVN Sampling]
    MVN --> SimData[Simulated Data]
    SimData --> Repartition[Repartition Sim. Data from maxmMds]
    Repartition --> SimLower[Sim. Lower]
    Repartition --> SimGlobal[Sim. Global]
    Repartition --> SimUpper[Sim. Upper]
    SimLower --> Est2[Block Covariance Estimation]
    SimGlobal --> Est2
    SimUpper --> Est2
    Est2 --> Mahalanobis[Mahalanobis Calculation]
    Mahalanobis --> SimLowerMds[Simulated Lower mMds]
    Mahalanobis --> SimGlobalMds[Simulated Global mMds]
    Mahalanobis --> SimUpperMds[Simulated Upper mMds]
  
```


We generated 2000 simulated HT-H295R datasets using multivariate normal sampling.

For each simulated dataset:

- Estimate three different covariance matrices based on weak responders (lower), all data (global), and strong responders (upper).
- Derive new mMds using these covariance matrices for a total of three sets of mMds values to compare.

U.S. Environmental Protection Agency
Office of Research and Development

Changes in covariance matrices from data simulation suggest that the covariance structure is stable, leading to reproducible mMds.




A. Comparison of the correlation of the three estimated covariance matrices.

- Correlation of the covariance of steroid hormone measures are largely the same.
- Variance of the steroid hormone measures is also similar.

B. Scatterplot of the difference between the original mMd and the median of the simulated mMd for the three covariance types.

- Practically no difference was observed between the simulated mMds and the original mMds (dashed identity line).


What is the true type I error rate (false positive rate) and the power to detect fold-changes in steroid hormones?



A. Estimated type I error rate of a simulate true negative HT-H295R response profile at two α levels and the three covariance matrix types.

B. The power to detect experimental significance using the mMd approach.

- Fold-change effect sizes ≥ 1.5 -fold resulted in sufficient power to detect significant effects on steroidogenesis.
- The lowest power was observed for steroid hormone changes in both estrone (E1) and estradiol (E2).



Heatmap showing the expression of 100 genes across 10 cell lines, categorized by Acromioclavicular-relevant and Rest of Pathway. The heatmap is divided into four horizontal sections: Chrysin, Chlorzoxazone, Metoprolol, and Fluoxetine. The color scale ranges from -2 (blue) to 2 (red).

Legend:

- \log_{10} meanRMSD: 10, 25
- \log_{10} fold-change: 2, 5

Cell Lines (Columns):

- MDA-MB-231
- MDA-MB-468
- MDA-MB-453
- MDA-MB-436
- MDA-MB-435
- MDA-MB-434
- MDA-MB-433
- MDA-MB-432
- MDA-MB-431
- MDA-MB-430

Gene Categories (Rows):

- Chrysin
- Chlorzoxazone
- Metoprolol
- Fluoxetine

Steroid response heatmap for putative aromatase inhibitors.

- 72 out of 766 chemical samples had a putative aromatase inhibitory signature (1.5-fold decreases in both E1 and E2).
- Hierarchical clustering of androstenedione, testosterone, E1, and E2 responses identified four predominant clusters.
- Known aromatase inhibitors decrease estrogens *and* androgens but have myriad effects on upstream steroid hormone patterns.

Chemical Name	Cas No.	maxMw	HT-H295R Estrone	HT-H295R Estradiol	HT-H295R Fold Change	HT-H295R Aromatase Positive	NVS Aromatase Positive
4,4'-Oxydianiline	101-80-4	18.35	↓	-	Yes	Yes	No
Clofibrate	23593-75-1	18.35	↓	↓	Yes	Yes	No
Cyproheptadine	94361-06-5	8.58	↓	↑	Yes	No	Yes
Epothilone B	13365-98-8	14.68	↓	↓	Yes	Yes	Yes
Fadrozole	102678-31-3	16.90	↓	↓	Yes	Yes	Yes
hydrochloride							
Fenarimol	60168-98-9	16.70	↓	↓	Yes	Yes	Yes
Flusilazole	85509-19-9	9.27	↓	↓	Yes	Yes	No
Imazali	35554-44-0	22.62	↓	↓	Yes	Yes	Yes
Letrozole	112809-51-5	14.02	↓	↓	Yes	Yes	Yes
Myclobutanil	88671-89-0	16.43	↓	↓	Yes	Yes	Yes
Prochloraz	67747-09-5	18.56	↓	↓	Yes	Yes	Yes
Propiconazole	60207-90-1	5.14	-	-	No	No	Yes
SRP150106	NOCAS_47362	9.06	↓	↓	Yes	Yes	Yes
Tetraconazole	112281-77-3	3.41	↓	-	No	No	Yes
Triadimenol	55219-65-3	17.25	↓	↓	Yes	Yes	Yes
Triflumizole	68694-11-1	17.19	↓	↓	Yes	Yes	Yes
Vatalanib	212141-51-0	8.34	↓	↓	Yes	Yes	No

Concordance of putative aromatase inhibitors from the Tox21/ToxCast aromatase assays and HT-H295R.

- 17 putative selective aromatase inhibitors from Tox21 confirmatory screening were tested in both the ToxCast NVS aromatase assay and HT-H295R.
- 14 of the 17 putative aromatase inhibitors were considered selective positives in HT-H295R, and 12 were considered positives in the ToxCast NVS assay.
- 9 chemicals were positive in both the ToxCast NVS assay and HT-H295R.

[illegible]

- The mMd appears to be robust to changes in the covariance matrix derived from different effect size partitions of the HT-H295R chemical space.
- The observed type I error rates were conservative and similar to the approximated values used in the critical threshold calculation, suggesting that the hit call method used for the mMd approach is appropriate and robust.
- An effect size of a 1.5-fold increase in hormone levels results in a maxmMd response value greater than the critical threshold with a power of 0.8 or higher, except for changes in both estrogen steroid hormones.
- The HT-H295R assay as implemented can identify aromatase inhibitors, but the myriad responses across the majority of the steroid hormone measures for these chemicals suggests that proper mechanistic evaluation requires multiple timepoints to better model the complex and dynamic steroidogenesis pathway present in H295R cells.
- Inclusion of orthogonal aromatase assays can increased confidence in identifying aromatase bioactivity.
- Removing chemical samples that had BMDs within the cytotoxicity/mitochondrial toxicity 'burst' range using the selectivity score, and then ordering by the AUC estimates appeared to efficiently rank active chemicals with steroid hormones and known steroidogenesis disruptors ranking highest.

This poster does not reflect US EPA policy. D.E.H. was supported by appointment to the Research Participation Program of the U.S. Environmental Protection Agency, Office of Research and Development, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the U.S. EPA.